Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 1
2007 2
2009 3
2010 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
Nakajima H, Kakui N, Ohkuma K, Ishikawa M, Hasegawa T. Nakajima H, et al. Among authors: kakui n. J Pharmacol Exp Ther. 2005 Feb;312(2):472-81. doi: 10.1124/jpet.104.075465. Epub 2004 Oct 1. J Pharmacol Exp Ther. 2005. PMID: 15466246
Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.
Ishikawa M, Shinei R, Yokoyama F, Yamauchi M, Oyama M, Okuma K, Nagayama T, Kato K, Kakui N, Sato Y. Ishikawa M, et al. Among authors: kakui n. J Med Chem. 2010 May 13;53(9):3840-4. doi: 10.1021/jm901890s. J Med Chem. 2010. PMID: 20384344
Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, Nakatani Y, Ohsawa F, Nishikawa N, Sugai M, Suzuki M, Aoki K, Kitaguchi H. Kakui N, et al. J Pharmacol Exp Ther. 2006 May;317(2):562-70. doi: 10.1124/jpet.105.099705. Epub 2006 Jan 25. J Pharmacol Exp Ther. 2006. PMID: 16436501
11 results